<DOC>
	<DOCNO>NCT00963833</DOCNO>
	<brief_summary>Multiple Sclerosis ( MS ) mainly know disease young middle adulthood approximately 5 % MS case worldwide involve child young 16 year . The aim care child Multiple Sclerosis prevent least delay neurological cognitive impairment well progression disease far possible . Therefore , crucial diagnose disease early stage immunomodulatory treatment available delay progression Multiple SclerosisTreatment immunomodulatory agent Betaferon® child diagnose RRMS 12 year old approve health authority . The aim observational study obtain data safety , tolerability , effectiveness Betaferon® daily living condition . As non-interventional observational study , routine clinical practice observe . The application diagnostic measure medication well physician visit follow normal routine decide upon treat physician recognition package insert .</brief_summary>
	<brief_title>Study Evaluating Betaferons Safety Tolerability In Pediatric Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Treatment naive child adolescents 12 16 year age inclusion diagnosis RRMS accord revise McDonald Poser criterion decision take investigator treat Betaferon . The local Betaferon product information must consider . Contraindications state local Betaferon product information ; warning precaution must consider .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Non-interventional</keyword>
</DOC>